


Amendments to the Claims

This claim listing will replace all prior versions of claims and claim listings in the
 5 application:

WHAT IS CLAIMED:

1. (Currently amended) A compound structurally represented by Formula I






Formula (I)

10 or pharmaceutically acceptable salts thereof wherein:

R¹ is

-CH₂N R³R⁴,

-CONR³R⁴,



R² is


-Hydrogen,

-NH-(C₁-C₆) alkyl,


-NH-(C₁-C₄) alkylene-phenyl,

-NH(C₃-C₆)cycloalkyl,

-NR³R⁴,



20



wherein;

R^3 is hydrogen,

5 $-(C_1-C_4)$ alkyl,

R^4 is

$-(C_1-C_4)$ alkyl,

$-(C_1-C_4)$ alkylene -phenyl,

10 wherein R^3 and R^4 can cyclize to form, together with the nitrogen to which they
are attached, a five or six-membered ring, wherein optionally one of the carbons of
the ring formed by said nitrogen, R^3 , and R^4 , is replaced by a nitrogen or oxygen,
and wherein said ring is optionally further substituted by R^5 , and


R^5 is hydrogen,

15 $-(C_1-C_4)$ alkyl, wherein optionally R^5 forms a 3 to five membered ring
with the nitrogen containing ring to which it is attached,

$-(C_1-C_4)$ alkylene -N-pyrrolidinyl,


$-(C_1-C_4)$ alkylene -N- piperidinyl;

provided that when R^1 is $-\underline{CH_2}N R^3 R^4$ or $-\underline{CONR^3 R^4}$, then R^2 is



20

2. (Original) A compound structurally represented by Formula II,



(II)

or pharmaceutically acceptable salts thereof wherein:

Z is -carbonyl-, or -CH₂-,

5 R² is




-Hydrogen,

-NH-(C₁-C₆) alkyl,

-NH-(C₁-C₄) alkylene-phenyl,

-NH(C₃-C₆)cycloalkyl,

10 -NR³R⁴,



wherein;

15 R³ is hydrogen,

-(C₁-C₄) alkyl,

R⁴ is

-(C₁-C₄) alkylene -phenyl,

20 wherein R³ and R⁴ can cyclize to form, together with the nitrogen to which they are attached, a five or six-membered ring, wherein optionally one of the carbons of the ring formed by said nitrogen, R³, and R⁴, is replaced by a nitrogen or oxygen, and wherein said ring is optionally further substituted by R⁵, and


R⁵ is hydrogen,






-(C₁-C₄) alkyl, wherein optionally R⁵ forms a 3 to five membered ring with the nitrogen containing ring to which it is attached,

-(C₁-C₄) alkylene -N-pyrrolidinyl,

5 -(C₁-C₄) alkylene -N- piperidinyl.







3. (Original) The compound of claim 1, wherein R¹ is CONR³R⁴, and R³ and R⁴ cyclize to form, together with the nitrogen to which they are attached, a five membered ring, and said ring is further substituted by -CH₂- pyrrolidinyl.
4. (Original) The compound of claim 1, wherein R¹ is CH₂NR³R⁴, and R³ and R⁴ cyclize to form, together with the nitrogen to which they are attached, a five membered ring, and said ring is further substituted by -CH₂- pyrrolidinyl.
5. (Original) The compound of claim 3 wherein R² is N R³R⁴, and R³ and R⁴ cyclize to form, together with the nitrogen to which they are attached, a five membered ring.
6. (Original) The compound of claim 4 wherein R² is N R³R⁴, and R³ and R⁴ cyclize to form, together with the nitrogen to which they are attached, a five membered ring.
7. (Currently amended) The compound of claim 1, further represented by any one of the formula (~~Example 1~~) to (~~Example 18~~) selected from the group consisting of:


Example Number	
1	

2	 <chem>O=C1C2=CC=CC=C2C3CCN(C3)C1C4CCCC4</chem>
3	 <chem>O=C1C2=CC=CC=C2C3CCN(C3)C1C4CCCC4</chem>
4	 <chem>O=C1C2=CC=CC=C2C3CCN(C3)C1C4CCCC4</chem>
5	 <chem>O=C1C2=CC=CC=C2C3CCN(C3)C1C4CCCC4</chem>
6	 <chem>O=C1C2=CC=CC=C2C3CCN(C3)C1C4CCCC4</chem>

8





7	
8	
9	
10	
11	

12	
13	
14	
15	
16	
17	



or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

8. (Currently amended) A pharmaceutical composition which comprises a compound of ~~any of~~ claims 1-7 and a pharmaceutically acceptable carrier.
- 5 9. (Currently amended) A method for treatment or prevention of a cognitive disorder which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of ~~any of~~ Claims 1-7.
- 10 10. (Original) The method of Claim 9 wherein the antagonist is a pharmaceutical composition of claim 8.
- 10 11. (Currently amended) A method for treatment or prevention of obesity which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of ~~any of~~ Claims 1-7.
12. (Original) The method of Claim 11 wherein the antagonist is a pharmaceutical composition of claim 8.
- 15 13. (Currently amended) A method for treatment or prevention of a wakefulness disorder which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of ~~any of~~ Claims 1-7.
14. (Original) The method of Claim 13 wherein the antagonist is a pharmaceutical composition of claim 8.
- 20 15. (Canceled).
16. (New) A compound selected from the group consisting of:

Example Number	
7	
10	
11	
12	

or a pharmaceutically acceptable salt thereof.